GlassScriptPhysician profile
Christopher L Winters
NPI 1275628398
$152,052.12
in general payments reported to CMS, 2019-2025
41 companies · $25K in 2025
The $25K reported for 2025 was more than what 98% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $9,830 · 2021: $7,601 · 2022: $13K · 2023: $26K · 2024: $57K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $61K · Travel and Lodging: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,750 · Food and Beverage: $8,417 · Education: $7,900 · Consulting Fee: $4,855 · Honoraria: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $61,200.00 |
| Travel and Lodging | $13,243.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,750.00 |
| Food and Beverage | $8,416.56 |
| Education | $7,900.00 |
| Consulting Fee | $4,855.00 |
| Honoraria | $2,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $122,270.47 | 2019-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Sanara Medtech INC. | $11,523.65 | 2022-2025 | Celleraterx, Celleraterx |
| Medline Industries LP | $10,238.65 | 2019-2021 | |
| Convatec INC. | $2,428.39 | 2019-2024 | |
| Smith+Nephew, INC. | $1,218.68 | 2019-2025 | Grafix Pl, Oasis, Grafix |
| Organogenesis INC. | $698.96 | 2021-2025 | Affinity, Puraply, Affinity |
| Urgo Medical North America, LLC | $528.36 | 2023-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgoclean Ag, Urgok2 |
| Paratek Pharmaceuticals, INC. | $416.47 | 2019-2024 | Nuzyra |
| Stryker Corporation | $413.60 | 2021-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Polynovo North America LLC | $311.51 | 2021-2024 | Novosorb Btm |
| Solventum Corporation | $287.97 | 2025 | Activ.A.C., 3m Cavilon, 3m Coban |
| Aroa Biosurgery Incorporated | $203.76 | 2022-2025 | |
| Kci USA, INC. | $189.25 | 2019-2021 | |
| Integra Lifesciences Corporation | $149.01 | 2019 | |
| Bioventus LLC | $141.96 | 2023 | Theragenesis Bilayer Wound Matrix |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$192,006.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.